Knight Therapeutics Inc.
GUD.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 67.65M | 69.84M | 64.24M | 54.54M | 60.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 67.65M | 69.84M | 64.24M | 54.54M | 60.76M |
| Cost of Revenue | 34.64M | 35.25M | 33.31M | 29.39M | 30.80M |
| Gross Profit | 33.01M | 34.59M | 30.93M | 25.15M | 29.96M |
| SG&A Expenses | 18.68M | 18.54M | 17.20M | 13.91M | 17.15M |
| Depreciation & Amortization | 8.20M | 8.53M | 8.06M | 8.17M | 8.56M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.30M | 66.56M | 62.26M | 54.60M | 60.07M |
| Operating Income | 2.35M | 3.28M | 1.97M | -61.00K | 693.40K |
| Income Before Tax | 445.80K | 521.10K | -5.30M | -19.22M | 6.63M |
| Income Tax Expenses | 383.50K | 1.94M | -1.93M | -1.34M | -514.40K |
| Earnings from Continuing Operations | 62.30K | -1.42M | -3.37M | -17.88M | 7.15M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 62.30K | -1.42M | -3.37M | -17.88M | 7.15M |
| EBIT | 2.35M | 3.28M | 1.97M | -61.00K | 693.40K |
| EBITDA | 12.17M | 12.91M | 11.30M | 5.78M | 10.91M |
| EPS Basic | 0.00 | -0.01 | -0.03 | -0.17 | 0.07 |
| Normalized Basic EPS | 0.00 | -0.01 | 0.02 | -0.08 | 0.03 |
| EPS Diluted | 0.00 | -0.01 | -0.03 | -0.18 | 0.07 |
| Normalized Diluted EPS | 0.00 | -0.01 | 0.02 | -0.08 | 0.03 |
| Average Basic Shares Outstanding | 101.13M | 101.33M | 101.17M | 103.72M | 106.25M |
| Average Diluted Shares Outstanding | 101.13M | 101.33M | 101.17M | 103.72M | 106.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
